+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
A

Actively Recruiting

Researchers are evaluating neladalkib NVL-655 compared to alectinib in patients with treatment-naive, ALK-positive advanced Non-Small Cell Lung Cancer NSCLC. This Phase 3, randomized, controlled, open-label study aims to see if neladalkib can better prolong progression-free survival in this patient population. Patients have confirmed ALK rearrangement and have not received prior systemic anticancer treatment for NSCLC except certain chemotherapy under specific conditions. Participants are randomly assigned in equal numbers to receive either neladalkib at 150mg once daily or alectinib at 600mg twice daily, both given orally. The study treatment continues as per protocol, with approximately 225 patients in each treatment arm. This trial evaluates multiple outcomes including progression-free survival, overall survival, intracranial response rates, and safety measures over a period of up to five years after the first patient is dosed. Throughout the study, participants undergo regular assessments including imaging to measure tumor response and progression, laboratory tests to monitor safety, and patient-reported questionnaires to evaluate quality of life and lung cancer symptoms. Safety and adverse events are closely monitored. The total duration of participation can last up to five years, allowing for long-term observation of treatment effects and outcomes.

Age: 18Years +All GendersPhase 3
159 locations
P

Actively Recruiting

Researchers are evaluating treatments for advanced breast cancer that is hormone receptor HR-positive and HER2-low or ultralow, classified as non-luminal subtype by gene expression profiling PAM50. This phase II international study compares trastuzumab deruxtecan T-DXd with a physicians choice of CDK46 inhibitor plus endocrine therapy ET to see which better prolongs progression-free survival in these patients. Participants will be randomly assigned to receive either T-DXd at 5.4 mgkg body weight by intravenous infusion every 21 days or one of several CDK46 inhibitors palbociclib, ribociclib, or abemaciclib combined with an endocrine therapy fulvestrant, letrozole, anastrozole, or exemestane chosen by their doctor. Treatment will continue in 21-day cycles, and the study will assess outcomes over up to 25 months. During the study, participants will undergo regular assessments including imaging scans to evaluate tumor response and progression. Researchers will monitor progression-free survival, overall survival, response rates, quality of life, and safety through adverse event tracking. Follow-up and treatment adherence will be closely observed to understand the effects and tolerability of these therapies in this specific breast cancer subtype.

Age: 18Years +All GendersPhase 2
79 locations